Weiwei Sui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weiwei Sui has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Dehui Zou
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
85 shared publications - Gang An
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
85 shared publications - Lugui Qiu
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
85 shared publications - Shuhua Yi
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Tianjin Institutes of Health Science, Tianjin, China
85 shared publications - Yan Xu
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
85 shared publications - Yuting Yan
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
61 shared publications
Latest Publications
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 3. Mutations and immunoglobulin heavy chain variable (IGHV) fragments of patients.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 3. Mutations and immunoglobulin heavy chain variable (IGHV) fragments of patients.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 2. Treatment flow chart.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 2. Treatment flow chart.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 4. Change of lymphocyte subsets before and after treatment.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 4. Change of lymphocyte subsets before and after treatment.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 6. The outcomes and disease status of patients who completed the treatment.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 6. The outcomes and disease status of patients who completed the treatment.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 4. Factors associated with deep response rate after induction and at best response.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 4. Factors associated with deep response rate after induction and at best response.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 6. Swim lane plots of efficacy in patients treated with ZID.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 6. Swim lane plots of efficacy in patients treated with ZID.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplementary Table 1. Representativeness of Study Participants.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplementary Table 1. Representativeness of Study Participants.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 3.The results of chromosome karyotype in all the patients.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 3.The results of chromosome karyotype in all the patients.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 1. Schematic diagram of the research scheme.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 1. Schematic diagram of the research scheme.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 2.The modified criteria from IWWM-6.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 2.The modified criteria from IWWM-6.